Gerald Gellermann

Gerald currently works as Scientific Officer at Novartis TRD biologics. He is member of the Novartis ICHQ12 implementation team and leads the TRD biologics QbD and Control Strategy initiative. Prior to joining Novartis he gained professional experience in CMC and analytical development during his time at Roche from 2008 to 2015. Gerald currently also represents Novartis in the EFPIA analytical workstream supporting ICH Q2R2 and ICH Q14.